Seres Therapeutics

233 articles with Seres Therapeutics

• Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

  3/9/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 2023 at 8:40 a.m. ET.

• Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

  3/7/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.

• Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Seres Therapeutics, Inc. announced that on March 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 15,500 shares of its common stock to three new employees, consisting of stock options to purchase an aggregate of 9,250 shares of common stock and restricted stock units, covering an aggregate of 6,250 shares of its common stock.

• Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023

  2/28/2023

  Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on March 7, 2023 at 8:30 a.m. ET to discuss fourth quarter and full year 2022 results and provide a general business update.

• Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

  2/27/2023

  Seres Therapeutics, Inc. today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET.

• Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

  2/14/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of data from its Phase 3 ECOSPOR IV trial (ClinicalTrials.gov Identifier: NCT03183128) in JAMA Network Open that reinforce previously published results from the Phase 3 ECOSPOR III study on the investigational microbiome therapeutic SER-109 for the prevention of recurrent C. difficile infection (rCDI).

• Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

  2/8/2023

  Seres Therapeutics, Inc today announced that enrollment in Cohort 2 in its SER-155 Phase 1b study is underway.

• Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Seres Therapeutics, Inc. announced that on February 1, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 48,750 shares of its common stock to eleven new employees, consisting of stock options to purchase an aggregate of 32,500 shares of common stock and restricted stock units, covering an aggregate of 16,250 shares of its common stock.

• Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/13/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees.

• Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

  1/5/2023

  Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors.

• Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.

• Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

  11/22/2022

  Seres Therapeutics, Inc. announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.

• Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

  11/2/2022

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates.

• Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

  10/27/2022

  Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m. ET to discuss third quarter 2022 results and provide a general business update.

• Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

  10/26/2022

  Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review.

• Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings

  10/23/2022

  Seres Therapeutics, Inc., a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastroenterology 2022 Annual Meetings.

• Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

  10/19/2022

  Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.

• Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting

  10/12/2022

  Seres Therapeutics, Inc. announced today that it will be presenting data from its ECOSPOR IV trial of SER-109, an investigational microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI), at two leading industry conferences.

• Seres Therapeutics to Present at World Anti-Microbial Resistance Congress

  9/8/2022

  Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that Matthew Henn, Ph.D., Chief Scientific Officer at Seres, will be presenting at the World Anti-Microbial Resistance Congress being held on September 7-8, 2022 in National Harbor, Maryland.

• Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

  9/7/2022

  Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for SER-109 for the prevention of recurrent C. difficile infection (rCDI).